HIGHLIGHTS
- who: Caroline Dartigeas from the chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) and mantle cell lymphoma (MCL) in France have published the article: FIRE Study: Real-World Effectiveness and Safety of Ibrutinib in Clinical Practice in Patients with CLL and MCL, in the Journal: (JOURNAL) of August/30,/2018
- what: The short PFS time in patients with MCL reported in the study (12.4 months) might have been influenced partly by the majority of patients who were assessed as having a high or intermediate sMIPI score and partly by the real-world analysis.
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.